Series A · Healthtech
Abram Scientific raises $11.75m Series A led by Octapharma
The financing supports CoagCare development, clinical milestones and a planned US regulatory submission.
A diagnostics investment for a critical-care manufacturer
Octapharma led Abram Scientific’s $11.75m Series A, alongside existing and new investors affiliated with the University of Colorado Anschutz.
Abram plans to advance CoagCare through clinical milestones toward FDA 510(k) clearance. The system was not cleared for US marketing at the February announcement. For Octapharma, which supplies therapies in haematology and critical care, the transaction represents its first major diagnostics investment.
Funding history
Series A · This round$11.8M